Zalevsky Jonathan's Form 4 filing
Nektar Therapeutics (NKTR) · filed Aug 21, 2025
- Accession no.
- 0000950170-25-110775
- Filed
- Aug 21, 2025
- Trade date
- Aug 19, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $19.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zalevsky JonathanCIK 0001789857 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | Common Stock | SSaleDisposed | −725 | $26.59 | −$19,277.75 | 19,668 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | Common Stock | AGrant or awardAcquired | +16,666 | $0.00 | $0 | 16,666 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.